title: Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates.
abstract: We have tested the suitability of chromaffin-like carotid body glomus cells for dopamine cell replacement in Parkinsonian rats. Intrastriatal grafting of cell aggregates resulted in almost optimal abolishment of motor asymmetries and deficits of sensorimotor orientation. Recovery of transplanted animals was apparent 10 days after surgery and progressed throughout the 3 months of the study. The behavioral effects were correlated with the long survival of glomus cells in the host brain. In host tissue, glomus cells were organized into glomerulus-like structures and retained the ability to secrete dopamine. Several weeks after transplantation, dopaminergic fibers emerged from the graft, reinnervating the striatal gray matter. The special durability of grafted glomus cells in the conditions of brain parenchyma could be related to their sensitivity to hypoxia, which is known to induce cell growth, excitability, and dopamine synthesis. This work should stimulate research on the clinical applicability of carotid body autotransplants in Parkinson's disease.
authors.affiliation: Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Spain.
authors.forename: E F
authors.initials: EF
authors.lastname: Espejo
authors.forename: R J
authors.initials: RJ
authors.lastname: Montoro
authors.forename: J A
authors.initials: JA
authors.lastname: Armengol
authors.forename: J
authors.initials: J
authors.lastname: López-Barneo
mesh_terms: D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002344:Carotid Body / Q000166:cytology / Q000637:transplantation*; D003342:Corpus Striatum / Q000737:chemistry / Q000601:surgery*; D004195:Disease Models, Animal; D004298:Dopamine / Q000032:analysis / Q000172:deficiency / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D006085:Graft Survival; D008297:Male; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000601:surgery*; D051381:Rats; D017208:Rats, Wistar; D013565:Sympatholytics; D014738:Vibrissae / Q000502:physiology
chemical_list: D015259:Dopamine Agents; D013565:Sympatholytics; D016627:Oxidopamine; D000661:Amphetamine; D004298:Dopamine